Biotechnology company Dendreon Corporation, has developed what is believed to be a method for getting around prostate cancer’s ability to suppress the immune system’s cancer surveillance mechanisms. XVIVO visualized the mechanism of disease and also the proposed mechanism of action of a new class of drugs for fighting cancer’s immunosuppressant abilities.

“The animations that we developed with XVIVO garnered international acclaim and received praise from renowned dermatology experts.”
Vice President, Management Supervisor, Ogilvy Healthworld Medical Education